Evidence map›Paper›PMID 42125218›Full record

ReviewDrug design, development and therapy2026

Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib.

Muhammad Latif, Sana Mazhar, Mussarat Tasleem, Abdulmajeed Alqurashi, Muhammad Arfan, Zaman Ashraf, Muhammad Sohail Zafar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Molecular Profiling of Soil-DerivedCurrent issues in molecular biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad LatifCentre for Genetics and Inherited Diseases (CGID), Taibah University, Madinah, 42353, Kingdom of Saudi Arabia.
Sana Mazhar *Mirpur University of Science and Technology (MUST), Mirpur, Azad Jammu and Kashmir (AJK), 10250, Pakistan.
Mussarat Tasleem *Department of Chemistry and Chemical Engineering, Lahore University of Management Sciences, Lahore, Pakistan.
Abdulmajeed AlqurashiDepartment of Biology, College of Science, Taibah University, Medinah, 42353‎, Kingdom of Saudi Arabia.
Muhammad ArfanDepartment of Chemistry, School of Natural Sciences (SNS), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan.
Zaman AshrafDepartment of Chemistry, Rawalpindi Women University, Rawalpindi, 46300, Pakistan.
Muhammad Sohail ZafarDepartment of Clinical Sciences, College of Dentistry, Ajman University, Ajman, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a prominent approach in cancer treatment, leading to the development of several poly(ADP-ribose) polymerase inhibitors (PARPi), which have demonstrated substantial progress in clinical trials and efficacy in the management of ovarian cancer (OC), breast cancer (BC), and solid tumors (STs). These PARPi are approved for several cancers, including BC and OC. Among PARPi, Talazoparib (Talzenna

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug DiscoveryOvarian NeoplasmsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsDrug DevelopmentFemaleHumansPoly(ADP-ribose) PolymerasesAntineoplastic AgentsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerasestalazoparibbreast cancerclinical trialsovarian cancersynthetic strategiesthird-generation inhibitor

Identifiers

PMID42125218
PMCPMC13158130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.